The Roctavian program was originally acquired from University College London and appears to have limited commercial potential due to ongoing reimbursement issues in the US and EU. BioMarin has ...
Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...
BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN), a pharmaceutical company with a market capitalization of $13.15 billion, announced on Monday the appointment of Timothy P. Walbert to its ...
BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...
A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...
BioMarin Pharmaceutical BMRN is scheduled to report fourth-quarter and full-year 2024 earnings on Feb. 19, after market close. In the last reported quarter, BMRN’s earnings beat estimates by 16. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results